CVRx, Inc. CVRX R2K
Healthcare · Medical Devices · United States
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
READ MORE ›$5.58
-15.90% 1Y
Market & Price
Market Cap
$148.07M
Current Price
$5.58
High / Low (52W)
$10.81 / $4.74
Beta
0.87
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.10
Price to Book
5.07
P/S
2.51
EV/EBITDA
-2.75
Dividend Yield
-
Profitability & Returns
ROCE
-51.92%
ROE
-106.96%
ROA
-27.25%
Profit Margin
-89.14%
Op Margin
-82.34%
EPS (Latest Qtr)
$-0.50
EPS (TTM)
$-2.01
Balance Sheet & Liquidity
Debt/Equity
2.04
Quick Ratio
8.58
Current Ratio
10.20
Debt
$59.40M
Total Assets
$104.79M
Current Assets
$101.65M
Working Capital
$88.33M
Ownership
Promoter Holding
9.33%
Chg in Prom Hold
-
FII / Inst Holding
63.57%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$135.16M
Total Revenue (TTM)
$59.07M
EBITDA
$-49.21M
Free Cash Flow
$-23.05M
Operating Cash Flow
$-39.57M
Shares Outstanding
26.54M
Gross Margin
86.18%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
36.11%
Profit 5Y
-9.56%
Revenue (YoY)
19.60%
Earnings (YoY)
-
PROS
- Compounding revenue at 36.1% over 5 years.
CONS
- Earnings shrank at -9.6% CAGR over 5 years.
- Trading 48.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVRX CVRx, Inc. R2K | 5.58 | - | $148.07M | - | -51.92% | -106.96% | 36.11% | -9.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.25M | 997.00K | 2.86M | 3.12M | 3.40M | 4.08M | 5.03M | 6.19M | 7.98M | 9.50M | 10.51M | 10.77M | 11.81M | 13.37M | 12.35M | 13.59M | 14.69M | 16.02M | 14.77M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.04M | 2.14M | 1.94M | 2.20M | 1.89M |
| Gross Profit | 905.00K | 785.00K | 1.99M | 2.21M | 2.52M | 3.13M | 3.83M | 4.85M | 6.65M | 7.98M | 8.82M | 9.15M | 9.91M | 11.12M | 10.31M | 11.45M | 12.75M | 13.82M | 12.88M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.75M | 25.83M | 25.02M | 25.01M | 25.04M |
| Operating Income | -3.06M | -3.04M | -4.22M | -5.67M | -7.29M | -9.91M | -11.01M | -10.13M | -12.16M | -11.75M | -9.53M | -22.23M | -13.97M | -13.01M | -13.44M | -14.38M | -12.27M | -11.18M | -12.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.13M | -13.07M | -11.20M | -10.34M | -11.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46M | 1.47M | 1.48M | 1.42M | 1.55M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.77M | -14.74M | -12.87M | -11.94M | -13.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.00K | -3.00K | -3.00K | -7.00K | 1.00K |
| Net Income | -3.67M | -3.23M | -8.63M | -17.75M | -6.13M | -9.99M | -11.07M | -9.83M | -11.37M | -11.65M | -9.01M | -22.19M | -14.03M | -13.10M | -13.77M | -14.74M | -12.87M | -11.93M | -13.12M |
| Diluted EPS | - | - | -23.92 | -48.48 | -0.30 | -0.49 | -0.54 | -0.48 | -0.55 | -0.56 | -0.43 | -1.04 | -0.65 | -0.57 | -0.53 | -0.57 | -0.49 | -0.46 | -0.50 |
| R&D Expense | 2.13M | 1.50M | 1.75M | 2.25M | 1.70M | 2.26M | 2.35M | 2.29M | 3.42M | 3.28M | 2.70M | 3.06M | 2.77M | 2.50M | 2.52M | 2.47M | 3.15M | - | 3.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 6.05M | 13.04M | 22.47M | 39.30M | 51.29M | 56.65M |
| Cost of Revenue | - | - | 5.00M | 6.26M | 8.33M | 8.31M |
| Gross Profit | 4.61M | 9.40M | 17.47M | 33.04M | 42.96M | 48.34M |
| Operating Expenses | - | - | 60.00M | 76.14M | 102.45M | 99.61M |
| Operating Income | -11.51M | -25.97M | -42.53M | -43.10M | -59.49M | -51.27M |
| EBITDA | - | - | -40.74M | -38.73M | -54.89M | -46.74M |
| Interest Expense | - | - | 165.00K | 1.80M | 4.40M | 5.83M |
| Pretax Income | - | - | -41.32M | -41.05M | -59.91M | -53.32M |
| Tax Provision | - | - | 109.00K | 147.00K | 55.00K | -18.00K |
| Net Income | -14.11M | -43.08M | -41.43M | -41.20M | -59.97M | -53.31M |
| Diluted EPS | - | -4.16 | -2.02 | -1.99 | -2.65 | -2.04 |
| R&D Expense | 6.41M | 7.50M | 9.95M | 11.63M | 11.13M | 11.13M |
Compounded Sales Growth
| 5 Years: | 36.11% |
| 1 Year: | 19.60% |
Compounded Profit Growth
| 5 Years: | -9.56% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -15.90% |
| 6 Months: | -44.14% |
| 3 Months: | -31.62% |
| 1 Month: | -18.78% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 64.78M | - | 124.94M | 115.23M | 133.41M | 104.79M |
| Current Assets | - | - | - | 122.88M | 112.09M | 129.81M | 101.65M |
| Cash & Equivalents | - | 59.11M | - | 106.19M | 90.57M | 105.93M | 75.71M |
| Inventory | - | - | - | 6.96M | 10.98M | 12.11M | 12.21M |
| Receivables | - | - | - | 5.50M | 7.55M | 9.27M | 10.66M |
| Total Liabilities | - | 28.03M | - | 15.76M | 39.28M | 62.36M | 65.47M |
| Current Liabilities | - | 7.98M | - | 8.09M | 7.86M | 10.76M | 13.32M |
| Long Term Debt | - | 19.28M | - | 6.75M | 29.22M | 49.27M | 49.51M |
| Total Debt | - | - | - | 7.09M | 30.61M | 50.43M | 50.50M |
| Total Equity | -279.04M | -293.24M | - | 109.18M | 75.95M | 71.06M | 39.32M |
| Shares Outstanding | - | - | - | 20.63M | 20.88M | 25.32M | 26.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.10M | - | -42.68M | -39.02M | -39.14M | -40.17M |
| Investing Cash Flow | -311.00K | - | -685.00K | -591.00K | -1.36M | -580.00K |
| Financing Cash Flow | 49.78M | - | 7.49M | 23.98M | 55.87M | 10.52M |
| Capital Expenditure | -311.00K | - | -685.00K | -591.00K | -1.36M | -580.00K |
| Free Cash Flow | -16.41M | - | -43.36M | -39.61M | -40.51M | -40.75M |
| Net Change in Cash | - | - | -35.87M | -15.63M | 15.37M | -30.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 76.2% | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| Operating Margin % | -190.2% | -199.2% | -189.3% | -109.7% | -116.0% | -90.5% |
| Net Margin % | -233.1% | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| ROE % | 4.8% | - | -37.9% | -54.2% | -84.4% | -135.6% |
| ROCE % | -20.3% | - | -36.4% | -40.1% | -48.5% | -56.0% |
Shareholding Pattern
Insiders
9.33%
Institutions
63.57%
Public Float
70.11%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 15.17% | 4.02M | $22.46M |
| 2 | NEA Management Company, LLC | 7.64% | 2.03M | $11.31M |
| 3 | Blackrock Inc. | 3.87% | 1.03M | $5.73M |
| 4 | GSK plc | 3.80% | 1.01M | $5.62M |
| 5 | Vanguard Capital Management LLC | 3.43% | 911.31K | $5.09M |
| 6 | Royal Bank of Canada | 2.66% | 706.95K | $3.94M |
| 7 | Balyasny Asset Management LP | 2.38% | 630.81K | $3.52M |
| 8 | Silvercrest Asset Management Group, LLC | 2.16% | 572.02K | $3.19M |
| 9 | Parkman Healthcare Partners LLC | 1.62% | 429.51K | $2.40M |
| 10 | Geode Capital Management, LLC | 1.61% | 427.07K | $2.38M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVRX
No recent headlines available.